Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs

Cequier A.; Barrachina L.; Romero A.; Vitoria A.; Zaragoza P.; Vazquez F. J.; Rodellar C.

首页> 外文期刊>Human gene therapy >Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs

【24h】

Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs

机译：由主要组织相容性复合物（MHC）介导的同种异体标牌间充质干细胞（MSCs）的体液免疫反应：考虑到MSC治疗安全性和疗效的问题

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Human gene therapy》 |2019年第11期|共1页
作者
Cequier A.; Barrachina L.; Romero A.; Vitoria A.; Zaragoza P.; Vazquez F. J.; Rodellar C.;
展开▼
作者单位

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

Univ Zaragoza Zaragoza Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs [J] . Cequier A., Barrachina L., Romero A., Human gene therapy . 2019,第11期

机译：由主要组织相容性复合物（MHC）介导的同种异体标牌间充质干细胞（MSCs）的体液免疫反应：考虑到MSC治疗安全性和疗效的问题
2. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. [J] . C McMenamin, P G Holt The Journal of Experomental Medicine . 1993,第3期

机译：对吸入可溶性蛋白抗原的天然免疫应答涉及主要的组织相容性复合物（MHC）I类限制的CD8 + T细胞介导的但MHC II类限制的CD4 + T细胞依赖性的免疫偏差，导致选择性抑制免疫球蛋白E的产生。
3. Biosafety Evaluation of Equine Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) by Systematic Pathogen Screening in Peripheral Maternal Blood and Paired UC-MSCs [J] . Biopreservation and biobanking . 2020,第2期

机译：通过系统病原体筛选在外周母体血液和配对UC-MSCs中的大二脐脐源性间充质细胞（UC-MSCs）生物安全评价
4. SCALED-UP EXPANSION OF EQUINE CORD BLOOD MESENCHYMAL STEM CELLS (MSCS) FROM 10ML STIRRED SUSPENSION BIOREACTORS TO 100ML COMPUTER CONTROLLED STIRRED SUSPENSION BIOREACTORS USING COMPUTATIONAL FLUID DYNAMIC MODELING [C] . Erin Roberts, Tylor Walsh, Thomas G. Koch, Scale-up and manufacturing of cell-based therapies V . 2017

机译：利用计算流体动力学模型从10ML搅拌悬浮生物反应器到100ML计算机控制的搅拌悬浮生物反应器，将马鞭草血液间充质干细胞（MSCS）扩大规模
5. Maintaining the self-renewal and multipotential capacity of human mesenchymal stem/progenitor cells (MSCS) from bone marrow stroma in vitro to ensure efficacy in vivo. [D] . Larson, Benjamin Lee. 2009

机译：体外维持来自骨髓基质的人间充质干/祖细胞（MSCS）的自我更新和多能能力，以确保体内功效。
6. Allogeneic major histocompatibility complex‐mismatched equine bone marrow‐derived mesenchymal stem cells are targeted for death by cytotoxic anti‐major histocompatibility complex antibodies [O] . A.K. Berglund, L.V. Schnabel -1

机译：同种异体主要组织相容性复合物错配的马骨髓间充质干细胞被细胞毒性抗主要组织相容性复合物抗体杀死
7. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers [O] . Alix K. Berglund, Matthew B. Fisher, Kristin A. Cameron, 2017

机译：转化生长因子-β2下调马骨髓间充质干细胞的主要组织相容性复合物（mHC）I和mHC II表面表达而不改变其他表型细胞表面标志物

Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs

著录项

相似文献

相关主题

期刊订阅